Add BrightSurf on Google Email

NIH/National Institute of Neurological Disorders and Stroke


Study finds multiple sclerosis drug slows brain shrinkage

A clinical trial of over 250 participants with progressive multiple sclerosis found that ibudilast slowed down brain shrinkage compared to a placebo. The study showed a difference of approximately 2.5 milliliters of brain tissue between the two groups, but it is unclear if this translates to improved symptoms or function.

SourceNIH/National Institute of Neurological Disorders and Stroke·JournalNew England Journal of Medicine·DateAug 29, 2018

Next generation ALS drug silences inherited form of the disease in animal models

Researchers have discovered a second-generation drug that can silence the gene responsible for inherited ALS by injecting it into rodents. The new version of the drug is more effective at reducing SOD1 protein production and delaying disease progression. It may be ready for early-stage clinical trials.

SourceNIH/National Institute of Neurological Disorders and Stroke·JournalJournal of Clinical Investigation·DateJul 25, 2018

Self-tuning brain implant could help treat patients with Parkinson's disease

A new, fully implanted deep brain stimulation device uses real-time brain signals to fine-tune its signaling, reducing side effects and improving symptom control in Parkinson's patients. The adaptive system was shown to be equally effective as traditional stimulation methods in initial short-term studies.

SourceNIH/National Institute of Neurological Disorders and Stroke·JournalJournal of Neural Engineering·DateMay 29, 2018

Scientists uncover brain circuits behind putting up a fight or freezing in place

A recent study published in Nature found that the ventral midline thalamus (vMT) plays a crucial role in determining how animals respond to visual threats. The vMT sends information primarily to two brain areas, the basolateral amygdala and the medial prefrontal cortex, which turn out to be critical in determining reactions.

Brain-scan guided emergency stroke treatment can save more lives

A new study by the Endovascular Therapy Following Imaging Evaluation for the Ischemic Stroke (DEFUSE 3) trial demonstrated that brain-scan guided emergency stroke treatment can be effective up to 16 hours after symptom onset. The treatment led to improved outcomes, including increased functional independence and survival rates.

SourceNIH/National Institute of Neurological Disorders and Stroke·JournalNew England Journal of Medicine·DateJan 24, 2018

NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research

The National Institutes of Health has awarded four grants to establish a coordinated scientific research effort on myalgic encephalomyelitis/chronic fatigue syndrome. Researchers will collaborate on projects, share data, and engage with the ME/CFS community to advance knowledge and potential treatments for this debilitating disease.

Scientists give star treatment to lesser-known cells crucial for brain development

A new study published in Neuron confirms that lab-grown astrocytes mature at the same rate as human brains, providing a valuable technique to investigate their role in brain development and disease. The findings have significant implications for understanding the roots of neurological disorders such as schizophrenia and autism.

Midlife cardiovascular risk factors may increase chances of dementia

A large NIH-funded study found that middle-aged Americans with vascular health risk factors such as diabetes and high blood pressure are more likely to develop dementia later in life. The study analyzed data from 15,744 participants over 25 years and found a strong link between midlife vascular health and the risk of developing dementia.

Study finds worsening outcomes in service members 5 years after mild blast-induced concussion

A recent study published in JAMA Neurology found that US military service members who experienced a mild concussion after blast injury may continue to experience mental health symptoms and decreased quality of life for at least five years. The study also highlights the need for more effective, long-term treatment strategies.